FindTrial
Sign In

JNJ-68284528

DRUG5 trials

Sponsors

Janssen - Cilag International, Janssen Cilag International, Janssen Research & Development, LLC

Conditions

Multiple MyelomaNewly Diagnosed Multiple Myeloma

Phase 1

A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-Cell Maturation Antigen (BCMA) in Participants With Relapsed or Refractory Multiple Myeloma
CompletedNCT03548207
Janssen Research & Development, LLCMultiple Myeloma
Start: 2018-06-29End: 2022-08-23Updated: 2025-07-30

Phase 2

A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma
Active, not recruitingNCT04133636
Janssen Research & Development, LLCMultiple Myeloma
Start: 2019-11-07End: 2029-09-03Updated: 2026-03-17
A Phase 2, Multicohort Open-Label Study of JNJ-68284528, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA in Subjects with Multiple Myeloma CARTITUDE-2
Active, not recruitingCTIS2023-506587-13-00
Janssen - Cilag InternationalMultiple Myeloma
Start: 2020-01-30Target: 56Updated: 2025-09-02
A Phase 2 Multicohort Trial to Further Characterize the Efficacy and Safety of Ciltacabtagene Autoleucel
RecruitingCTIS2025-521975-30-00
Janssen Cilag InternationalNewly Diagnosed Multiple Myeloma
Start: 2025-10-03Target: 33Updated: 2025-10-29

Unknown Phase

Individual Patient Investigational New Drug (IND) Expanded Access Program of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy for Participant With Multiple Myeloma
NCT04452994
Janssen Research & Development, LLCMultiple Myeloma
Updated: 2025-06-13

Related Papers

Earlier use of ciltacabtagene autoleucel (cilta-cel) is associated with better immune fitness and stronger immune effects as shown by correlative analysis of peripheral blood and the bone marrow tumor microenvironment (TME) from the CARTITUDE-4 study
Blood2025-11-03
Long-term progression-free survival benefit with ciltacabtagene autoleucel in standard-risk relapsed / refractory multiple myeloma
Blood2025-11-03
Long-term (≥5 year) remission and survival after treatment with ciltacabtagene autoleucel (cilta-cel) in CARTITUDE-1 patients (pts) with relapsed/refractory multiple myeloma (RRMM).
Journal of Clinical Oncology2025-05-285 citations
Cost-per-responder analysis of patients with lenalidomide-refractory multiple myeloma receiving ciltacabtagene autoleucel in CARTITUDE-4
Frontiers in Immunology2024-08-215 citations
Efficacy and safety of ciltacabtagene autoleucel ± lenalidomide maintenance in newly diagnosed multiple myeloma with suboptimal response to frontline autologous stem cell transplant: CARTITUDE-2 cohort D.
Journal of Clinical Oncology2024-06-016 citations
Ciltacabtagene autoleucel in patients with lenalidomide-refractory multiple myeloma: CARTITUDE-2 cohort A expansion subgroup.
Journal of Clinical Oncology2024-06-01
FDA Approval Summary: Ciltacabtagene Autoleucel for Relapsed or Refractory Multiple Myeloma
Clinical Cancer Research2024-05-0734 citations
Long-term remission and survival in patients with relapsed or refractory multiple myeloma after treatment with LCAR-B38M CAR T cells: 5-year follow-up of the LEGEND-2 trial.
2024-04-2462 citations
The Phase 2 CARTITUDE-2 Trial: Updated Efficacy and Safety of Ciltacabtagene Autoleucel in Patients with Multiple Myeloma and 1-3 Prior Lines of Therapy (Cohort A) and with Early Relapse after First Line Treatment (Cohort B)
Blood2023-11-0227 citations
Are Pivotal CART Trials Representative of Population at Risk?
Blood2023-11-02
Developments of Multiple Myeloma Treatment During the COVID-19 Era
Oncology Times2023-10-05
S202: CARTITUDE-1 FINAL RESULTS: PHASE 1B/2 STUDY OF CILTACABTAGENE AUTOLEUCEL IN HEAVILY PRETREATED PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
HemaSphere2023-08-0112 citations
Extrapolation of Survival Data Using a Bayesian Approach: A Case Study Leveraging External Data from Cilta-Cel Therapy in Multiple Myeloma.
2023-06-043 citations
CARTITUDE-1 final results: Phase 1b/2 study of ciltacabtagene autoleucel in heavily pretreated patients with relapsed/refractory multiple myeloma.
Journal of Clinical Oncology2023-06-01106 citations
Plain language Summary of the CARTITUDE-1 Study of Ciltacabtagene Autoleucel for the Treatment of People with Relapsed or Refractory Multiple Myeloma
Future Oncology2023-06-015 citations
BCMA CAR-T induces complete and durable remission in refractory plasmablastic lymphoma
Journal for ImmunoTherapy of Cancer2023-05-0119 citations
B09 CARTITUDE-2 COHORT B 18-MONTH FOLLOW-UP: CILTACABTAGENE AUTOLEUCEL (CILTA-CEL), A BCMA-DIRECTED CAR-T CELL THERAPY, IN PATIENTS WITH MULTIPLE MYELOMA (MM) AND EARLY RELAPSE AFTER INITIAL THERAPY
HemaSphere2023-05-011 citations
P28 EFFICACY AND SAFETY OF CILTACABTAGENE AUTOLEUCEL (CILTA-CEL) IN PATIENTS WITH PROGRESSIVE MULTIPLE MYELOMA (MM) AFTER EXPOSURE TO NON-CELLULAR ANTI-B-CELL MATURATION ANTIGEN (BCMA) IMMUNOTHERAPY
HemaSphere2023-05-01
Adjusted comparison of outcomes between patients from CARTITUDE-1 <i>versus</i> multiple myeloma patients with prior exposure to proteasome inhibitors, immunomodulatory drugs and anti-CD38 antibody from the prospective, multinational LocoMMotion study of real-world clinical practice
Haematologica2022-12-2219 citations
Ciltacabtagene Autoleucel (Cilta-cel), a BCMA-Directed CAR-T Cell Therapy, in Patients with Multiple Myeloma (MM) and Early Relapse after Initial Therapy: CARTITUDE-2 Cohort B 18-Month Follow-up
Blood2022-11-1525 citations

42 more papers not shown